The U.S. Food and Drug Administration (FDA) is informing patients and healthcare providers about the potential for overdose, under certain clinical use conditions, when using ENFit low dose tip (LDT) syringes.
The FDA is aware of the potential for overdose if the user does not clear the moat area around the tip of the ENFit LDT syringe before administering a medication. The moat area is unique to the design of the ENFit LDT syringes.
The FDA is providing recommendations for patients and healthcare providers to promote the safe use of ENFit LDT syringes, including steps users can take to optimize dose accuracy.